ABBV-399, a C-Met Antibody–Drug Conjugate That Targets Both MET –Amplified and C-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1568
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

C-Met Inhibitors

Infectious Agents and Cancer
Cancer ResearchEpidemiologyOncologyInfectious Diseases
2013English

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2013English

C-Met Proto-Oncogene (MET; HGFR); Hepatocyte Growth Factor/Scatter Factor (HGF/SF)

Science-Business eXchange
2014English

Targeting C-Met Receptor Overcomes TRAIL-Resistance in Brain Tumors

PLoS ONE
Multidisciplinary
2014English

C-Met Expression in Primary Tumors and Their Corresponding Distant Metastases

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2008English

Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors

Cancer Research
Cancer ResearchOncology
2016English

Molecular Imaging of C-Met Tyrosine Kinase Activity

Analytical Biochemistry
BiochemistryCell BiologyMolecular BiologyBiophysics
2011English

Plexin B1 Suppresses C-Met in Melanoma: A Role for Plexin B1 as a Tumor-Suppressor Protein Through Regulation of C-Met

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2010English

A Novel One-Armed Anti-C-Met Antibody Inhibits Glioblastoma Growth in Vivo

Clinical Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy